Note: Funding Information: This work was supported by the Netherlands Organization for Scientific Research Graduate Program (grant no. 022.004.018 to R.J.G.). L.M. is supported by Vici grant number 91815608 from the Netherlands Organization for Scientific Research. L.M. and L.B. have received funding for an investigator-initiated study to validate LAIR-1 as a therapeutic target in an experimental animal model of respiratory syncytial virus infection.